Ginsenoside Rb1 attenuates erythropoietin-exacerbated vascular calcification in chronic kidney disease through BMP2-dependent Smad1/5/9 inhibition
Rb1 mitigates EPO-aggravated VC in CKD by disrupting BMP2/Smad1/5/9 signaling, positioning it as a promising molecular intervention strategy to reduce EPO-induced vascular toxicity.
Authors
- Weijian Xiong (ORCID: https://orcid.org/0000-0001-6920-1909)
- Xunjia Li (ORCID: https://orcid.org/0000-0002-1182-2638)
- Deyu Zuo (ORCID: https://orcid.org/0000-0001-6901-1742)
- Ying Li (ORCID: https://orcid.org/0000-0002-3868-9021)
- Zhixin Xu (ORCID: https://orcid.org/0000-0002-3294-268X)
- Jie Zhou (ORCID: https://orcid.org/0009-0004-6063-6358)
- Yan Luo
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- First People's Hospital of Chongqing (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- CytoJournal
- Published
- 2025-09-19
- DOI
- https://doi.org/10.25259/cytojournal_70_2025
- Citations
- 3
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.31